ClinicalTrials.Veeva

Menu

The Role of VOCs, Airway Mucins and Airway Microbiome in Bronchopulmonary Dysplasia (INFANCY)

A

Antwerp University Hospital (UZA)

Status

Enrolling

Conditions

Bronchopulmonary Dysplasia

Treatments

Diagnostic Test: Breath test
Other: Endotracheal aspirates
Other: Vaginal swab
Other: Placental samples
Other: Throat swabs

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Bronchopulmonary dysplasia (BPD), the most common respiratory complication of extremely preterm birth, significantly impacts healthcare with high morbidity and mortality rates.

Despite the well-established primordial role of inflammation and oxidative stress in the development of BPD, clinical practice does not incorporate the testing for biomarkers associated with the development of BPD. The diagnosis of BPD based on required respiratory support at 36 weeks PML, stresses the need for an early prediction tool which could identify patients with high levels of these biomarkers. This on its turn, could also improve treatment approaches in clinical practice which are currently mostly supportive or non-specific and do not target underlying pathophysiologic pathways.

Secondly, mucin expression aim to play a rol in other respiratory diseases, whereas in BPD only the potential role of MUC1 was explored.

Thirdly, the composition of the airway microbial composition of an infant is assumed to be influenced by different factors. From early on in pregnancy the airway microbiome of the infant is formed, offering a protective role against pathologies. On the other hand, the role of the airway microbiome in the development of BPD remains unclear and needs to be elucidated.

The threefold aim of this study is as follows:

I. The development of a non-invasive breath test that allows early detection of bronchopulmonary dysplasia, using the potential of VOCs in exhaled breath as biomarkers for inflammation and oxidative stress.

II. The exploration of the composition and diversity of the airway microbiome in infants with BPD, their association with exhaled VOCs and the exploration of the placental and vaginal microbiome.

III. The detection of potential alterations in airway mucin expression in BPD patients.

Through this comprehensive approach, we seek to gain a deeper understanding of how these mutual associations may contribute to the later development of BPD.

In total 140 preterm infants, including 70 BPD patients and 70 preterm controls, born below 30 weeks' gestation at the Antwerp University Hospital will be included.

Full description

After birth, a swab and samples will be collected from the placenta, next to a maternal vaginal swab for microbiome analysis. Breath samples, two oropharyngeal swabs and endotracheal aspirates - in case intubated - will be collected from the infant on different days in the first 28 days of life.

At 36 weeks PMA, BPD is diagnosed if the infant still requires respiratory support. Infants diagnosed with BPD will undergo a one-time capillary (or venous) blood gas test to assess the degree of severity of lung damage, i.e. grade of alveolar hypoventilation by means of hypercapnia.

All enrolled participants, regardless of BPD diagnosis, will have two clinical follow-up study visits after discharge to home. At 6 months corrected age, a chest CT will be performed in severe BPD-cases to assess lung structure.

Enrollment

140 estimated patients

Sex

All

Ages

Under 3 days old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Born at a gestational age < 30 weeks

Exclusion criteria

  • Major congenital defect or disorder
  • Patients with an unstable general condition as deemed by the attending neonatologist

Trial design

140 participants in 2 patient groups

Preterm infants
Description:
all included infants will undergo a breath test and two throat swabs, in case the infant is intubated also endotracheal aspirates will be collected
Treatment:
Other: Throat swabs
Other: Endotracheal aspirates
Diagnostic Test: Breath test
Mothers of preterm infants
Description:
placental biopsies, a placental swab and a vaginal swab will be taken after birth
Treatment:
Other: Vaginal swab
Other: Placental samples

Trial contacts and locations

1

Loading...

Central trial contact

Kristien Vanhaverbeke, MD, PhD; Inès Ghys, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems